Physicians' Academy for Cardiovascular Education

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

Aug. 28, 2017

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
##SCROLLER_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Role of PCSK9 in the regulation of LDL cholesterol

Sep. 12, 2016

LDL cholesterol, the LDL receptor pathway & PCSK9

Sep. 10, 2016

The future perspectives for care for patients with high Lp(a)

May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium

CME accredited Satellite Symposium held at ESC on August 26, 2017 in Barcelona focussed on 'PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies'

Update of ACC Expert consensus decision pathway on management of atherosclerotic CVD risk

A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways - Endorsed by the National Lipid Association

Sep. 20, 2017 - news

Data of the FOURIER and SPIRE trials called for an update of the 2016 ACC consensus paper on the role of non-statin therapies for LDL-C-lowering in the management of ASCVD risk.

PCSK9 inhibition also safely lowers CV event in patients with diabetes

EASD 2017 - Lisbon, Portugal

Sep. 15, 2017 - news
FOURIER sub-analysis shows that lowering LDL-C levels with evolocumab significantly and consistently reduced CV events also in patients with diabetes, without increasing the risk of new onset diabetes in non- or pre-diabetics.

EASD 2017 FOURIER sub-analysis shows that lowering LDL-C levels with evolocumab significantly and consistently reduced CV events also in patients with diabetes, without increasing the risk of new onset diabetes in non- or pre-diabetics.

Also at very low achieved LDL-c is ‘the lower better’ for cardiovascular risk

ESC 2017 - Barcelona

Aug. 27, 2017 - news

ESC 2017 FOURIER trial data show that after 2.2 years of follow-up, very low LDL-c levels are still associated with further reduction of CV events, without an increase in safety events.

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

ESC 2017 - Barcelona

Aug. 28, 2017
A secondary analysis of the FOURIER analysis divided patients in five categories of achieved LDL-c after 4 weeks of evolocumab treatment. Patients with <0.5 mmol/L showed the lowest CV event rate.

ESC 2017 A secondary analysis of the FOURIER analysis divided patients in five categories of achieved LDL-c after 4 weeks of evolocumab treatment. Patients with <0.5 mmol/L showed the lowest CV event rate.

LDL-c still reduced after 1 year with siRNA against PCSK9

ESC 2017 - Barcelona

Aug. 28, 2017
Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.

ESC 2017 Safe and optimal treatment regimen identified for inclisiran, an siRNA against PCSK9, which is still effective after one year in the ORION-1 trial.

PCSK9 antibody does not increase HbA1c, fasting glucose or diabetes risk

Aug. 16, 2017 - Sattar N, et al. - Am J Cardiol 2017

In the OSLER-1 and OSLER-2 open-label extension studies, treatment with evolocumab for the duration of 1 year had no apparent effect on glucose homeostasis, but led to a slight weight increase.

PCSK9 loss-of-function variants associate with lower LDL-C

Aug. 9, 2017 - Kent ST, et al. - Circ Cardiovasc Genet. 2017

A large meta-analysis of nine studies confirmed association of PCSK9 loss-of-function variants with lower LDL-C levels and lower coronary heart disease risk, but not with stroke risk.

Anti-PCSK9-vaccination has anti-atherogenic effects in mice

June 26, 2017 - news

Anti-PCSK9 vaccination (AT04A) lowers LDL-c, atherosclerosis and inflammatory markers in mouse model for atherosclerosis. Phase I study into this vaccine has started

PCSK9 inhibition is associated with regression of tendon xanthomas in FH

June 21, 2017 - Bea AM et al. - Atherosclerosis 2017
In a case-control study on HeFH patients treated with potent statins, the addition of a PCSK9 antibody (evolocumab or alirocumab) resulted in a greater decrease of tendon xanthomas thickness after 3 years of treatment.

In a case-control study on HeFH patients treated with potent statins, the addition of a PCSK9 antibody resulted in a greater decrease of tendon xanthomas thickness after 3 years of treatment.

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA
Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works, it is safe, and you cannot force biology

PCSK9 Expert Opinions Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works – even lower is even better; it is safe, and you cannot force biology – it takes a long time to get atherosclerosis, so it will also take some time to get rid of it.

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA
According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

PCSK9 Expert Opinions According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.